<div id="readability-page-1"><div> RTI opioid treatment program-level measures of retention highlight opportunities for quality improvementRESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 /PRNewswire/ -- A new study published in JAMA Network Open and authored by experts at RTI International, an independent scientific research institute, has found that many opioid treatment programs (OTPs) across the U.S. are struggling to keep patients engaged. According to the study, at typical opioid treatment programs, 61% of Medicaid patients remained in care beyond the first month, but, among the bottom quarter of programs, only 40% remained in treatment for at least one month.&#34;For opioid use disorder, treatment retention is one of the strongest predictors of recovery and survival for patients experiencing opioid use disorder,&#34; said lead author Tami Mark, Ph.D., a Distinguished Fellow at RTI. &#34;This new measure offers OTPs a consistent benchmark that shows how their retention rates align with national patterns, enabling programs to pinpoint strengths, isolate gaps and prioritize targeted improvements.&#34;RTI researchers created case-mix adjusted retention measures using Medicaid claims data from 2018 to 2023. In 2023, the measures included more than 1,100 OTPs, 432,000 treatment episodes, and 261,000 patients.The measures reveal a wide variation in OTPs' retention rates:<ul><li>OTPs in the top 75% retained 73.5% of participants for 30 days, compared with 40.9% in the bottom 25%.</li><li>At 90 days, top OTPs retained 54.8%, while bottom–quartile programs retained 22.2%.</li><li>At 180 days, retention was 40.5% in the top group and 11.4% in the bottom group.</li></ul>RTI researchers Dylan DeLisle, MPH, Chelsea Katz, Ph.D.; William Dowd, Ph.D.; Daniel Barch, Ph.D.; Marianne Kluckman, MPH, also contributed to the study, which was supported by the NIH HEAL Initiative.Read the full studyLearn more about RTI's substance use researchAbout RTI InternationalRTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world's most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world's most challenging problems. For more information, visit www.rti.org.Media Contact: RTI International Media Relations 408153@email4pr.com 919-541-7300 <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMyZzbj1QSDcwMDMz"/> View original content:https://www.prnewswire.com/news-releases/new-quality-measures-reveal-wide-variation-in-opioid-treatment-programs-medicaid-patient-retention-rates-302669211.htmlSOURCE RTI International</div></div>

A study by RTI International published in JAMA Network Open reveals significant disparities in Medicaid patient retention rates among opioid treatment programs (OTPs) in the U.S. The research indicates that only 61% of Medicaid patients stay in care beyond the first month, with the bottom 25% of programs retaining just 40%. The study highlights the importance of treatment retention as a predictor of recovery and survival for patients with opioid use disorder. The findings suggest that OTPs can use these benchmarks to identify areas for improvement in patient engagement.

MorningStar

Direxion Healthcare Bull 3X

iShares Biotechnology ETF

VG Health

Iovance Biotherapeautics

Invesco S&P 500 Equal Weight Health Care ETF

Alkermes

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Elevance Health

Molina Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Phibro Animal Health

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Centene

Hookipa Pharma

ProShares Ultra Health Care ETF

Unitedhealth

Acadia Healthcare

CVS Health

Leverage Shares 2X Long UNH Daily ETF

SPDR S&P Health

iShares US Healthcare Providers

VanEck Biotech ETF

Indivior

New Quality Measures Reveal Wide Variation in Opioid Treatment Programs' Medicaid Patient Retention Rates